Recently, Pulike and its subsidiaries have been awarded 2 more new veterinary drug certificates! Up to now, Pulike and its subsidiaries have obtained 57 new veterinary drug registration certificates!
Luoyang Huizhong Biotechnology Co., Ltd. have jointly declared "Newcastle disease, infectious bronchitis, avian influenza (H9 subtype) and infectious bursal disease quadruple inactivated vaccine (N7a strain + M41 strain + SZ strain + rVP2 protein) " according to the regulations of Veterinary Drug Administration and Veterinary Drug Registration Measures, after review by the Ministry of Agriculture and Rural Development. +Ltd. jointly with the Veterinary Research Institute of Jiangsu Academy of Agricultural Sciences and other units declared "Duck infectious pluritis, E. coli diphasic vaccine (type 1 CZ12 strain + O78 SH strain)" as new veterinary drugs, the Ministry of Agriculture and Rural Affairs on July 27, 2021 publicized the issuance of "new veterinary drug registration certificate" (Ministry of Agriculture and Rural Affairs Notice No. 450) matters.
In 2017, we focused on building a high-quality
New veterinary drug name: Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), infectious bursal disease quadruple inactivated vaccine (N7a strain + M41 strain + SZ strain + rVP2 protein) in chickens
Registration classification: Class III
Main components: The vaccine contains inactivated chicken Newcastle disease virus strain N7a, chicken infectious bronchitis virus strain M41, avian influenza virus (subtype H9) strain SZ and infectious bursal disease virus VP2 protein.
Actions and Uses: For the prevention of Newcastle disease, infectious bronchitis, H9 subtype avian influenza and infectious bursal disease in chickens from 7 to 14 days of age, the immunization period is 4 months; for chickens over 14 days of age, the immunization period is 6 months.
Market background: Newcastle disease, chicken infectious bronchitis, H9 subtype avian influenza and chicken infectious bursal disease are important diseases that seriously endanger the poultry industry in China and the world, with a wide range of prevalence, high incidence and high mortality in case of mixed infection, causing huge economic losses to the poultry industry.
The quadruple inactivated vaccine (strain N7a + strain M41 + strain SZ + rVP2 protein) for Newcastle disease, infectious bronchitis, avian influenza (subtype H9) and infectious bursal disease in chickens developed by Pleco has the following advantages.